Medroxyprogesterone: Indications, Available Brands, Presentations, Administration and Interactions

This medication is usually used to regulate irregular menstrual cycles in women during the procreation period.

Medroxyprogesterone belongs to the class of medications called progestins. Progesterone is a female hormone.

In this way, the medroxyprogester has the ability to significantly reduce the effects of estrogen on tissues such as the endometrium and the mother.

Indications

Medroxyprogesterone has different uses:

In addition to Estrogen Replacement Therapy (ETS), it is used to:

  • Avoid the deposition of estrogen in the lining of the uterus.
  • Significantly reduce the risk of endometriosis failure .
  • It is also prescribed for irregular menstrual cycles.
  • It is applied in menstrual periods and abnormal or irregular menstrual bleeding.
  • Medroxyprogesterone is also used alone or in combination with other anti-cancer drugs to treat endometrial and breast cancer.

Available Brands

Unlike other medicines whose patent is in the hands of one or very few laboratories, in the case of medroxyprogesterone, it is available under several brands or different presentations.

A special brand of this medication may be available in all forms. In addition, some forms of this medication can not be used against all the conditions mentioned in this article.

The doctor may have suggested this medication to treat a condition that is not listed in this medication information article. Do not stop taking this medication without first consulting a doctor.

Presentations

2.5 mg:

Each tablet, pink-orange, biconvex, marked with the inscription “MED” to “2,5” on both sides Contains 2.5 mg medroxyprogesterone acetate. Inactive ingredients:

  • Lactose monohydrate.
  • Microcrystalline cellulose.
  • Croscarmellose sodium.
  • Magnesium stearate.
  • Sulfato de lauril de sodio a dioxido coloidal silico, FD & C Yellow # 10 se FD & C Yellow # 6.

5 mg:

Each round tablet, blue, biconvex and printed with “MED” to “5” on one side contains 5 mg of medroxyprogesterone acetate. Inactive ingredients:

  • Lactose monohydrate.
  • Microcrystalline cellulose.
  • Croscarmellose sodium.
  • Magnesium stearate.
  • Sodium lauryl sulfate.
  • Colloidal silico dioxide are FD & C Blue # 2.

Administration

The consumption of medroxyprogesterone should be in relation to medical prescription. The doses to be taken can not be random or say standardized but on the contrary, personalized to each person depending on their condition and ultimate purposes given to the medication in relation to the patient’s condition.

Thus we have that, for example, the recommended dose of medroxyprogesterone for adults is widely designed for the condition being treated and the response to work.

For hormone replacement therapy, the dose ranges from 2.5 mg per day to 10 mg per day for several specific days of the month.

For the treatment of abnormal menstruation, a typical dose of medroxyprogesterone is 5 to 10 mg per day for 10 days.

A typical dose for the treatment of breast cancer is 400 mg per day.

For the treatment of endometrial cancer , the dose is 200 mg 400 mg per day.

There are several factors that can be considered to determine the dose a person needs: weight, health and other medications. If the doctor recommends a different dose than those listed here, do not change the way you take the medication without first consulting it.

Unless medroxyprogesterone is part of the treatment for breast cancer, it should not be taken by women whose uterus is not intact.

The endometrial hyperplasia is treated for 12 to 14 consecutive days commencing on day 1 or 16 of the menstrual cycle.

The dose for contraception is 150 mg every 3 months injected intramuscularly or 104 mg injected subcutaneously every 3 months.

The dose for endometrial or renal cancer is 400-1000 mg weekly.

Interactions

Aminoglutethimide (Cytadren) may increase the elimination of medroxyprogesterone by the liver, which leads to a decrease in the concentration of medroxyprogesterone in the blood and, possibly, a reduction in the efficacy of medroxyprogesterone.